Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The Short Answer for Operators This Week
Three things drove the week of November 20, 2024, for behavioral health operators: the MHPAEA final rule took effect November 22, deal value in the sector jumped even as volume fell, and federal enforcement kept landing on the largest providers. If you run a treatment center, those three facts should be sitting on top of your Q1 planning documents.
The Mental Health Parity and Addiction Equity Act final rule published jointly by Treasury, DOL, and HHS carried an effective date of November 22, 2024, with staggered applicability starting with plan years on or after January 1, 2025. OPEN MINDS reported that for the twelve months ending November 15, 2024, behavioral health M&A deal count dropped 19% while aggregate value hit $400 million, a 324% jump year over year. And on the enforcement side, Acadia Healthcare paid $16.66 million to the United States to resolve DOJ allegations tied to unnecessary services, improper discharges, and staffing shortcomings.
None of these are abstractions. Each one changes what a founder, COO, or PE sponsor should be doing before year end.
MHPAEA: The November 22 Effective Date That Payers Are Already Reading
CMS, DOL, and Treasury jointly finalized the MHPAEA rule on September 9, 2024. The CMS summary lays out the core operator-relevant piece: nonquantitative treatment limitations (NQTLs) around network composition, prior authorization, and out-of-network reimbursement methodology must be no more restrictive for mental health and SUD benefits than for medical or surgical benefits.
The Departments framed the intent plainly. Regulators wrote that the final rules require plans to make sure people with covered MH or SUD conditions “do not face greater burdens on access to benefits” than they would face for medical or surgical care, per the CMS regulatory summary. That is not aspirational language. It is language your commercial payers are quoting back to you during utilization management appeals right now.
What operators in Florida, Tennessee, and Arizona should do this week:
- Pull denial data by level of care (Residential, PHP at ASAM Level 2.5 as an outpatient service, IOP at Level 2.1) and look for patterns that suggest a payer is applying an NQTL more restrictively to SUD than to a medical benchmark.
- Document your own concurrent review turnaround times so you have the data ready when a payer’s SIU audit or a state parity complaint lands.
Note: on May 15, 2025, DOL, HHS, and Treasury announced they would not enforce the portions of the 2024 rule that are new relative to the 2013 rule while litigation plays out. The Departments were explicit that “MHPAEA’s statutory obligations, as amended by the CAA, 2021, continue to have effect.” Comparative analyses remain a live obligation.
The M&A Data: Fewer Deals, Bigger Checks, and a New Buyer Mix
The headline from OPEN MINDS is that behavioral health deal count for the trailing twelve months ending November 15, 2024, sat at 67 transactions, down 19%, while total value hit $400 million, up 324%. Across all healthcare sectors, 1,373 deals closed with an aggregate value of $69 billion, an 8.8% drop in volume.
Read that carefully. Buyers are still writing checks. They are writing bigger ones. They are also being pickier about the platforms they will underwrite.
Two data points sharpen the picture. Mertz Taggart’s Q4 2024 report logged 155 total behavioral health transactions for the year across traditional M&A and growth deals, with 11 growth deals in Q4 alone worth about $170 million. And a JAMA Psychiatry study by Zhu, Greenberg, King, and Busch published May 1, 2024, documented significant state-by-state variation in private equity ownership of mental health and SUD facilities, with 6.2% of mental health clinics and 7.1% of SUD clinics under PE ownership through mid-2023.
What that means if you are considering a sale in Florida, Tennessee, or Ohio: the buyers looking at your business right now are more disciplined than the 2021 cohort. They will read your denials, your census trend by payer, your clinical staffing ratios, and your accreditation history before they debate multiple. If your operational backbone is weak, they will find it during quality of earnings.
Federal Enforcement: Acadia, Cerebral, and What Surveyors Are Watching
The Department of Justice recouped more than $2.9 billion under the False Claims Act in fiscal year 2024, with approximately $1.7 billion tied to healthcare. Behavioral health was on the list.
Two cases operators should read carefully.
Acadia Healthcare agreed to pay $16.66 million to the United States (plus $3.19 million to Florida, Georgia, Michigan, and Nevada) to resolve allegations involving billing for medically unnecessary inpatient behavioral health services, improper discharges, and staffing shortcomings between 2014 and 2017. Principal Deputy Assistant Attorney General Brian M. Boynton said the case reflects DOJ’s commitment to making certain “that federal healthcare programs pay only for services that are needed and properly provided,” per the DOJ announcement.
In November 2024, Cerebral agreed to pay more than $3.6 million in connection with practices tied to the unauthorized distribution of controlled substances between 2019 and 2022, as part of a non-prosecution agreement with the U.S. Attorney’s Office for the Eastern District. Two different companies. Two different failure modes. One common thread: documentation and clinical judgment that could not withstand a regulator reading the chart line by line.
If you run a residential or PHP program, treat these settlements as your surveyor focus list for 2025:
- Medical necessity documentation tied to the ASAM Criteria (Fourth Edition) level-of-care assignment, with a defensible reason for each continued stay.
- Discharge planning that is a real clinical decision, not a census management tool.
- Staffing ratios that match what your license and accreditation standards require, not what your labor budget wishes were true.
- Controlled substance prescribing workflows that hold up to DEA review.
What to Do Before Year End
If you are running a treatment center right now, this is a five-item list, not a strategy deck:
- Refresh your MHPAEA comparative analysis file. The CAA 2021 obligation is not paused. When a payer or state regulator asks, you should be able to hand it over in 48 hours.
- Run a mock survey on medical necessity and discharge documentation before any surveyor books an EOC tour. The Acadia settlement is a preview of what a serious surveyor or SIU auditor is looking for.
- Rebuild your pro forma with 2025 payer assumptions, not 2022 assumptions. If your feasibility study still uses pre-pandemic reimbursement and length-of-stay numbers, it is fiction.
- Get a diligence-ready compliance program and financial package built now if you are considering a transaction. Buyers in Florida, Tennessee, and Ohio are moving faster on clean assets and walking away from messy ones.
- Name your operational backbone weaknesses out loud to your leadership team. Founders who let their COOs work around a broken UM process for another quarter are the ones who show up in the next enforcement release.
Operators who spent November 2024 quietly tightening documentation and payer readiness will be the ones with a real growth story in 2025. The ones who treated the news as background noise will be the ones explaining to a buyer, or a regulator, why the file does not match the pitch deck.
Frequently asked questions
When did the 2024 MHPAEA final rule take effect, and does it still apply?
The 2024 MHPAEA final rule, issued jointly by DOL, HHS, and Treasury on September 9, 2024, became effective November 22, 2024, with staggered applicability dates starting with plan years on or after January 1, 2025, and continuing into 2026. On May 15, 2025, the Departments announced they would not enforce the portions of the 2024 rule that are new relative to the 2013 rule while ERISA Industry Committee litigation plays out, but they were explicit that MHPAEA’s statutory obligations under the CAA 2021, including the NQTL comparative analysis requirement, continue to have effect. Operators should keep treating comparative analyses and network adequacy as active compliance obligations.
What happened to behavioral health M&A volume and value around November 2024?
According to OPEN MINDS, the twelve months ending November 15, 2024, saw 67 behavioral health M&A deals, a 19% decline in count versus the prior period, while aggregate deal value hit $400 million, a 324% year-over-year increase. Mertz Taggart’s Q4 2024 report logged 155 total behavioral health transactions across traditional M&A and growth deals for the full year, with 11 Q4 growth deals worth about $170 million combined. Buyers are more selective and paying more for clean platforms.
What should operators take from the Acadia Healthcare $16.66 million settlement?
DOJ announced that Acadia Healthcare agreed to pay $16.66 million to the United States (plus $3.19 million to Florida, Georgia, Michigan, and Nevada) to resolve False Claims Act allegations tied to billing Medicare, Medicaid, and TRICARE for medically unnecessary inpatient behavioral health services, improper discharges, and staffing shortcomings between 2014 and 2017. For treatment center operators, the practical takeaway is that medical necessity documentation aligned to ASAM Criteria (Fourth Edition), defensible discharge decisions, and staffing that matches licensure and accreditation requirements are enforcement priorities, not paperwork exercises.
How much of the behavioral health sector is owned by private equity?
A May 2024 JAMA Psychiatry study by Zhu, Greenberg, King, and Busch documented that approximately 6.2% of mental health clinics and 7.1% of substance use disorder clinics were PE-owned based on transactions between January 2012 and July 2023, with significant state-by-state variation. In Colorado, Texas, and North Carolina, PE-owned practices accounted for roughly a quarter of all facilities providing mental health treatment. The trajectory since then has continued upward, with PE-backed platforms driving most add-on activity.
References
- Federal Register: Requirements Related to the Mental Health Parity and Addiction Equity Act (Final Rule, effective November 22, 2024)
- CMS: The Mental Health Parity and Addiction Equity Act (MHPAEA) overview
- DOL/HHS/Treasury: May 15, 2025 Statement Regarding Enforcement of the 2024 MHPAEA Final Rule
- OPEN MINDS: Behavioral Health Deal Values Grew By 324% in 2024
- Mertz Taggart: Q4 2024 Behavioral Health M&A Report
- U.S. Department of Justice: Acadia Healthcare to Pay $19.85M to Settle False Claims Allegations
- U.S. Attorney’s Office, Eastern District of New York: Cerebral $3.6M Non-Prosecution Agreement
- K&L Gates: DOJ Announces $2.9 Billion in FY 2024 False Claims Act Recoveries
- Zhu JM, Greenberg E, King M, Busch S. Geographic Penetration of Private Equity Ownership in Outpatient and Residential Behavioral Health. JAMA Psychiatry. 2024;81(7):732–735.